Clinical trial

Effect of Symbicort ® on GR in Sputum in COPD

NCT01787097

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2013-01-01

PhasePHASE4

Study timeline

Study start (unknown)2013-01-01Date precision: month

Registry last updated2020-11-23

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Chronic Obstructive Lung Diseaseunresolved

Interventions

Symbicort® total dose 400ug/12ugDRUG

Symbicort® total dose 800ug/24ugDRUG

Formoterol 24ugDRUG

BUD total dose 800ugDRUG

Sponsors & collaborators

Imperial College Londonlead sponsor

AstraZenecacollaborator

Mapped research locations

LondonUnited Kingdom1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01787097 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.